Full-Life Technologies to Participate in the ASCO 2025
Heidelberg, Germany, and Shanghai, China – May 29, 2025 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced that the Company will participate ASCO (“American Society of Clinical Oncology”) 2025 annual meeting and deliver a poster presentation on June 2nd, 2025, 9:00 AM CT.
Details of the poster presentation are as follows:
About [225Ac]Ac-FL-020
225Ac-FL-020 is a novel, potential best-in-class, next-generation PSMA-targeting radionuclide drug conjugate (“RDC”) that is currently in global Ph1 clinical trial. Its targeting vector, FL-020, was discovered using Full-Life's proprietary UniRDC™ platform, which enables significant improvement of drug uptake in the tumor while maintaining fast systemic clearance. In pre-clinical models, 225Ac-FL-020 has demonstrated potent anti-tumor activity and a favorable safety profile. The U.S. FDA has granted 225Ac-FL-020 Fast Track Designation.
About Full-Life Technologies
Full-Life Technologies ("Full-Life") is a clinical-stage, fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development.
